Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Revenue (2016 - 2025)

Historic Revenue for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $8.3 million.

  • Cumberland Pharmaceuticals' Revenue fell 873.3% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.3 million, marking a year-over-year increase of 1221.38%. This contributed to the annual value of $37.9 million for FY2024, which is 425.91% down from last year.
  • According to the latest figures from Q3 2025, Cumberland Pharmaceuticals' Revenue is $8.3 million, which was down 873.3% from $10.8 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' Revenue's 5-year high stood at $11.7 million during Q1 2025, with a 5-year trough of $8.1 million in Q3 2021.
  • In the last 5 years, Cumberland Pharmaceuticals' Revenue had a median value of $9.8 million in 2024 and averaged $9.8 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Revenue tumbled by 1892.19% in 2021 and then skyrocketed by 4138.14% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Revenue (Quarter) stood at $8.3 million in 2021, then increased by 9.66% to $9.1 million in 2022, then increased by 2.51% to $9.4 million in 2023, then rose by 11.57% to $10.4 million in 2024, then fell by 20.54% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $10.8 million for Q2 2025, and $11.7 million during Q1 2025.